PIT565
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
Pressure score
56
Momentum score
5
Why This Matters
Pfizer is a direct competitive threat because it has a development-stage program in Rheumatology · Small Molecule (PIT565) and could narrow Novartis's development lead.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Stage unknown
- Stage gap
- Stage comparison unavailable — competitor development phase not fully evidenced.
- Market share risk
- Moderate share risk if competitor advances before the signal sponsor establishes label leadership.
Strategic Action
Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
Pfizer's PIT565 directly references the same indication focus (Rheumatology · Small Molecule) as this signal.
Source: Pfizer
View source documentRelated Signal
Novartis initiates ascending dose study of PIT565 for rheumatoid arthritis
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #2 of 2
Roche
3 competitive findings
Top program: PIT565
- Pressure
- 58
- Momentum
- 51
- Threat
- direct competitor
- Stage
- Approved
58RocheMediumPIT565·Approved
Pfizer
2 competitive findings
Top program: PIT565
- Pressure
- 56
- Momentum
- 5
- Threat
- direct competitor
- Stage
- Stage unknown
56PfizerMediumPIT565·Stage unknown